1.. Introduction {#s6}
================

Since their invention in the 1980's,selective serotonin reuptake inhibitors (SSRIs) have been widely used to treat depressive disorders and anxiety disorders.[@B1] Common side effects include nausea,constipation,headache, anxiety, insomnia, and sweating.[@B2], [@B3], [@B4] Although increased suicidality (usually defined as suicidal ideation or suicidal behavior) has also been reported,[@B5], [@B6] the findings have been inconsistent. The first systematic review on the issue in 1991 did not find increased suicidality when comparing individuals treated with SSRIs to those treated with placebos,[@B7] but another systematic review did find that the use of SSRIs was associated with increased suicidality.[@B8] In 2004,the United States Food and Drug Administration (FDA) conducted a metaanalysis of 24 randomized controlled trials (RCT) among children and found a two-fold risk of suicidality when comparing individuals in the SSRI group with those in the placebo group.[@B9] Soon after,the FDA required a black-box warning on the packaging of all SSRI medications to warn of the possibility of exacerbation of depressive symptoms and increase in suicide risk among children,and to call for close monitoring of suicidality in children prescribed SSRIs.[@B10] In 2005 Gunnell and colleagues conducted a meta-analysis of RCTs submitted by pharmaceutical companies to the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) and reported a possible increase of self-harm in adults administered SSRIs (OR=1.57, 95% CI=0.99-2.55), but did not find any increase in suicide risk (OR=0.85, 95% CI=0.20-3.40).[@B11] In 2006 the United States FDA conducted an analysis using data from 372 RCTs among adults and did not find increased suicide risk associated with SSRIs,but did find evidence of increased suicide risk among the subgroup of young adults 18 to 24 years of age.[@B12]

In summary,given the varying methodologies employed in the existing systematic reviews and meta-analyses, it is not yet possible to be certain about the relationship of SSRI use and suicide risk. The purpose of systematic reviews and meta-analyses is to provide the best evidence for clinical practice. The value of the summary of the evidence provided in systematic reviews depends on the methodological quality of the reviews,[@B13] but there has,as yet,been no formal assessment of the quality of the available systematic reviews and meta-analyses about the relationship of SSRIs and suicidality. The current study seeks to evaluate the quality of previous systematic reviews on this topic using the Assessment of Multiple Systematic Reviews scale (AMSTAR).[@B14]

2.. Methods {#s7}
===========

2.1. Search strategies {#s7a}
----------------------

The identification of reviews included in this analysis is shown in Figure 1. Pubmed, Embase, The Cochrane Library, EBSCO, PsycINFO, Chinese National Knowledge Infrastructure,Chongqing VIP database for Chinese Technical Periodicals, WANFANG DATA,and the Chinese Biological Medical Literature Database (CBM) were searched for articles published by December 31,2013 using the following keywords: 'SSRI', 'SSRIs', 'antidepressant', 'placebo', 'suicide', 'suicidal','meta-analysis', 'systematic review', 'citalopram', 'escitalopram', 'fluoxetine', 'fluvoxamine', 'paroxetine', 'sertraline'. Reference lists of all included studies were hand checked for potential studies.

![Identification of included reviews](sap-26-05-248-g002){#sap-26-05-248-g002.tif}

2.2. Inclusion and exclusion criteria {#s7b}
-------------------------------------

All systematic reviews or meta-analyses of RCTs on the effect of SSRIs on the risk of suicide were included if: (a) the main outcome is suicidal ideation and/or suicidal behavior; (b) the control groups included a placebo control; and (c) the sample sizes and the numbers of outcome events were reported. Only articles published in English or Chinese were considered. Based on the recommendations of the 'Cochrane Handbook for Systematic Reviews of Interventions',[@B13] studies that were not about the incidence of adverse effects were excluded. Anthropological studies, non-systematic reviews, research protocols, case reports, and duplicated reports were also excluded.

2.3. Screening of studies {#s7c}
-------------------------

Literature management software (Endnote X5) was used to eliminate duplicated reports. Two of the authors (LW and WY) independently screened all titles and abstracts of studies and read the full-text of remaining studies. Studies were selected based on the aforementioned inclusion and exclusion criteria. The two authors discussed any disagreement about the inclusion of an article and a third author (RJ) was consulted when the two authors did not arrive at a consensus decision.

2.4. Quality evaluation {#s7d}
-----------------------

The Assessment of Multiple Systematic Reviews (AMSTAR) scale[@B14] was used to assess the methodological quality of the included reviews and meta-analyses. AMSTAR is an 11-item scale (shown in Table 2) developed in 2007 with good inter-rater reliability, face validity, and content validity that has been widely employed for measuring the methodological quality of systematic reviews. Two authors (LW and WY) independently evaluated the quality of included studies based on the AMSTAR scale,[@B14] rating each of the 11 items on a binary scale (i.e., 'yes', 'no' or 'not specified'). Disagreements in the ratings between the two raters were discussed and, if a consensus decision was not reached, a third author (LT) was called into make a final determination. The range of the overall quality score for each review was between 0 and 11.[@B15], [@B16] Based on the recommendations of the Canadian Agency for Drugs and Technologies in Health (CADTH),[@B27] the total score was used to classify the overall quality of each review as high (total score 9 to 11), moderate (score 5 to 8), or low (score 0 to 4).

2.5. Quality evaluation {#s7e}
-----------------------

Two authors (LW and LT) independently extracted relevant information to an Excel (Microsoft Excel 2007) sheet including the name of the authors, year of publication, number of included studies, combined sample size, number of outcome events, age of participants, type of medications, and diagnoses of participants. After independently coding the papers the two authors compared coding sheets and made a consensus decision about the few items that they had coded differently.

2.6. Data analysis {#s7f}
------------------

Quality ratings and other information were imported to SPSS 17.0 software for data analysis. Intra-class correlation coefficient (ICC) and Kappa statistics were used to evaluate the agreement of the original quality rating items.[@B17] Odds ratios (OR) were used to present the difference between groups of participants using SSRIs and groups using placebo. Stratified analyses were conducted based on variables related to the risk of suicide including age, type of medications, and diagnosis.

3.. Results {#s8}
===========

3.1. Study characteristics {#s8a}
--------------------------

As show in Figure 1 the search identified a total of 468 publications, all of which were in English-language journals. Review of the titles and abstracts found that 35 were duplicated reports, 8 were unrelated to the topic of interest,and a further 413 did not meet the inclusion criteria. This left 12 review articles that were included in the subsequent analyses.[@B7], [@B8],[@B11],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26]

shown in Table 1. All 12 articles were published in English from 1991 to 2011; 8 of them were published between 2005 and 2007.[@B8],[@B11],[@B18],[@B19],[@B20],[@B21],[@B24],[@B25] Among the 12 reviews,one third were among children and adolescents 19 years of age or younger;[@B18],[@B20],[@B24],[@B25] one third were among adults;[@B11],[@B19],[@B21],[@B22] and the remaining one-third did not specify the age range of participants.[@B7],[@B8],[@B23],[@B26] One review[@B8] did not specify the specific SSRI assessed; all others indicated the specific medication(s) that were compared to placebos; these included fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, and escitalopram. Nine of the 12 reviews[@B7],[@B8],[@B18],[@B19],[@B20],[@B21],[@B22],[@B24],[@B25] provided a description of the diagnoses of participants; most of the reviews considered the use of SSRIs in patients with depressive disorders or different types of anxiety disorders.

###### 

Characteristics of included reviews

  -----------------------------------------------------------------------------------------------------------
  study         trials/\       age\         SSRIs compared\             diagnoses\      outcome\
                participants   range        to placebo                  considered      measures
  ------------- -------------- ------------ --------------------------- --------------- ---------------------
  Beasley\      17/\           12-90        fluoxetine                  depression      suicidal acts\
  1991[@B7]     2334                                                                    suicidal ideation

  Khan\         14/\           general\     paroxetine; sertraline      not specified   suicide\
  2000[@B26]    6356           population                                                suicide attempt

  Fergusson\    189/\          general\     not specified               depression      suicide\
  2005[@B8]     18,413         population                                               suicide attempt

  Gunnell\      477/\          adults       fluoxetine; paroxetine;\    not specified   suicide\
  2005[@B11]    40,826                      sertraline; fluvoxamine;\                    self-harm\
                                            citalopram; escitalopram                    suicidal thoughts

  Dubicka\      unknown/\      6-18         fluoxetine; paroxetine;\    MDD             suicide attempt\
  2006[@B24]    2122                        sertraline; citalopram                      self-harm\
                                                                                        preparatory acts\
                                                                                        suicidal thought

  Hammad\       16/\           pediatric\   fluoxetine; paroxetine;\    MDD,OCD,SAD     suicidality
  2006[@B25]    2970           patients     sertraline; fluvoxamine;\                   
                                            citalopram                                  

  Apter\        5/\            \<18         paroxetine                  MDD,OCD,AD      suicidality
  2006[@B20]    1191                                                                    

  Bridge\       27/\           \<19         fluoxetine; paroxetine;\    MDD,OCD,AD      suicide attempt\
  2007[@B18]    3543                        sertraline; fluvoxamine;\                   preparatory act\
                                            and escitalopram or\                        suicidal ideation
                                            citalopram^a^                               

  Tauscher-\    53/\           18-65        fluoxetine                  Bulimia,OCD     suicidal behaviors\
  Wisniewski\   11,448                                                                  suicidal ideation
  2007[@B19]                                                                            

  Beasley\      18/\           \>18         fluoxetine                  MDD             suicidal behaviors\
  2007[@B21]    3751                                                                    suicidal ideation

  Stone\        372/\          15-99        fluoxetine; paroxetine;\    not specified   suicidality
  2009[@B23]    52,665                      sertraline; fluvoxamine;\                   
                                            citalopram; escitalopram                    

  Carpenter\    61/\           18-64        paroxetine                  depression,\    suicidal behaviors\
  2011[@B22]    14,911                                                  OCD,AD,PTSD     suicidal ideation
  -----------------------------------------------------------------------------------------------------------

SSRI,selective serotonin reuptake inhibitor                    MDD,major depressive disorder

OCD,obsessive-compulsive disorder                              AD,anxiety disorder

SAD,social anxiety disorder (subtype of anxiety disorder)      PTSD,posttraumatic stress disorder

a in this study results for escitalopram and citalopram were analyzed together,not separately

3.2. Results of quality evaluation {#s8b}
----------------------------------

As shown in Table 2, the ICC of the total AMSTAR scores for the 12 reviews between the two evaluating authors was 0.86, which indicates excellent inter-rater reliability in the overall quality assessment. However, 5 of the 11 individual items (items 1, 4, 7, 8, and 9) had Kappa values below 0.60 (the conventional level of 'fair' agreement[@B17]) and 2 items (items 9 and 4) had Kappa values below 0.40,indicating unacceptable agreement. Subsequent analysis of the items with poor inter-rater reliability identified two main causes: (a) the simple description of some of the items were interpreted differently by the two coders; (b) some articles had supplementary webbased materials that was accessed by one of the raters but not by the other rater.

The consensus assessments of the two coders of the 11 items shown in Table 2 indicate a surprising range in the quality of these 12 systematic reviews. Only 1 of the 12 reviews assessed the likelihood of publication bias,[@B18] only 2 provided a list of studies,[@B22],[@B25] only 3 assessed the scientific quality of the included studies,[@B18],[@B24],[@B25] and only 4 performed a comprehensive literature search.[@B7],[@B8],[@B18],[@B24] On the other hand,11 of the 12 reviews described the characteristics of the included studies,[@B7],[@B8],[@B11],[@B18],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26] 11 reviews appropriately combined the findings of the included studies,[@B7],[@B8],[@B11],[@B18], [@B19],[@B20],[@B22],[@B23],[@B24],[@B25],[@B26] and 10 reviews appropriately considered the scientific quality of included studies when formulating the final conclusions.[@B7],[@B8],[@B11],[@B18],[@B20],[@B21],[@B23],[@B24],[@B25],[@B26]

###### 

Assessment of Multiple Systematic Reviews (AMSTAR) scale ratings of the 12 included systematic reviews

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  AMSTAR criteria                                 Beasley\    Khan\        Fergusson\   Gunnell\     Dubicka\     Hammad\      Apter\       Bridge\      Tauscher-\    Beasley\     Stone\       Carpenter\   proportion\   kappa^a^
                                                  1991[@B7]   2000[@B26]   2005[@B8]    2005[@B11]   2006[@B24]   2006[@B25]   2006[@B20]   2007[@B18]   Wisniewski\   2007[@B21]   2009[@B23]   2011[@B22]   with item\    
                                                                                                                                                         2007[@B19]                                           present       
  ----------------------------------------------- ----------- ------------ ------------ ------------ ------------ ------------ ------------ ------------ ------------- ------------ ------------ ------------ ------------- ----------
  **1. Was an 'a priori' design provided?**       Yes         No           Yes          No           Yes          No           Yes          Yes          Yes           No           Yes          Yes          8/12          0.47

  **2. Was there duplicate study selection**\     Yes         No           Yes          No           No           Yes          Yes          No           No            Yes          Yes          Yes          7/12          0.68
  **and data extraction?**                                                                                                                                                                                                  

  **3. Was a comprehensive literature**\          Yes         No           Yes          No           Yes          No           No           Yes          No            No           No           No           4/12          0.63
  **search performed?**                                                                                                                                                                                                     

  **4. Was the status of publication used as**\   Yes         No           No           Yes          Yes          Yes          Yes          Yes          No            No           Yes          Yes          8/12          0.33
  **an inclusion criterion?**                                                                                                                                                                                               

  **5. Was a list of studies provided?**          No          No           No           No           No           Yes          No           No           No            No           No           Yes          2/12          0.75

  **6. Were the characteristics of the**\         Yes         Yes          Yes          Yes          Yes          Yes          Yes          Yes          No            Yes          Yes          Yes          11/12         0.63
  **included studies provided?**                                                                                                                                                                                            

  **7. Was the scientific quality of the**\       No          No           No           No           Yes          Yes          No           Yes          No            No           No           No           3/12          0.47
  **included studies assessed and**\                                                                                                                                                                                        
  **documented?**                                                                                                                                                                                                           

  **8. Was the scientific quality of the**\       Yes         Yes          Yes          Yes          Yes          Yes          Yes          Yes          No            Yes          Yes          No           10/12         0.56
  **included studies used appropriately**\                                                                                                                                                                                  
  **in formulating conclusions?**                                                                                                                                                                                           

  **9. Were the methods used to combine**\        Yes         Yes          Yes          Yes          Yes          Yes          Yes          Yes          Yes           No           Yes          Yes          11/12         0.25
  **the findings of studies appropriate?**                                                                                                                                                                                  

  **10. Was the likelihood of publication**\      No          No           No           No           No           No           No           Yes          No            No           No           No           1/12          0.63
  **bias assessed?**                                                                                                                                                                                                        

  **11. Was the conflict of interest stated?**    No          No           Yes          Yes          Yes          No           No           Yes          No            No           Yes          Yes          6/12          0.67

  **Total score (out of 11)**                     7           3            7            5            8            7            6            9            2             3            7            7            \-\--         0.86^b^

  **Overall methodological quality**\             M           L            M            M            M            M            M            H            L             L            M            M            \-\--         \-\--
  **(L=low,M=moderate,H=high)**                                                                                                                                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Kappa values for inter-rater reliability of the two independent coders who assessed each of the 11 items for the 12 reviews

^b^ Intraclass correlation coefficient (ICC) assessing the inter-rater reliability of the two independent raters of the total quality score for the 12 reviews

The range in the total AMSTAR score for the 12 reviews was 2 to 9 (theoretical range 0 to 11) and the mean (sd) was 5.92 (2.19). Based on CADTH criteria[@B27] for categorization of the AMSTAR total score,one study was considered high quality,[@B18] eight were considered moderate quality,[@B7],[@B8],[@B11],[@B20],[@B22],[@B23],[@B24],[@B25] and three were considered poor quality.[@B19],[@B21],[@B26]

3.3. Summary of the results of meta-analyses {#s8c}
--------------------------------------------

The summary of results is shown in Table 3. The high quality review reported a statistically significant higher risk of suicidal ideation or behavior when comparing the SSRI group with the placebo group (pooled OR=1.81, 95%CI=1.13-2.89).[@B18] Three of the eight moderate quality reviews[@B8], [@B20], [@B25] reported increased risk of suicidal ideation or behavior in the SSRI group compared to the placebo group (pooled OR=2.24 \[95%CI=1.05-4.76\],[@B8] 3.86 \[95%CI=1.45-10.26\],[@B20] and 1.89 \[95%CI=1.16- 3.06\][@B25]). None of the three low-quality reviews[@B19], [@B21], [@B26] reported differences in the risk of suicidal ideation or behavior between the SSRI and placebo groups.

### 3.3.1. Results stratified by age {#s8ca}

One high-quality review[@B18] and three moderate-quality reviews[@B18],[@B20],[@B25] were focused on SSRI use among children and adolescents; the high-quality review[@B18] and two of the three moderate-quality reviews[@B20],[@B25] reported increased risk of suicidal ideation or behavior in the SSRI group compared to the placebo group. There were two moderate-quality reviews[@B11],[@B22] and two low-quality reviews[@B19],[@B21] focused on SSRI use in adults; none of them found an increased risk of suicidal ideation or behavior associated with SSRI use.

### 3.3.2. Results stratified by type of medication {#s8cb}

As shown in Table 1,one of the 12 systematic reviews did not specify which SSRI was used,[@B8] five of the reviews only considered a single SSRI,[@B7], [@B19], [@B20], [@B21], [@B22] and the remaining six reviews compared two or more SSRIs to placebo.[@B11], [@B18], [@B23], [@B24], [@B25], [@B26] Six different SSRIs are considered in the reviews: paroxetine is considered in 8 reviews, fluoxetine in 7 reviews, sertraline in 6 reviews, fluvoxamine in 4 reviews, citalopram in 4 reviews, escitalopram in 2 reviews, and citalopram or escitalopram (not separately analyzed) in one review. As shown in Table 3,only two of the SSRIs were associated with elevated risk of suicidal ideation or behavior. One high-quality review[@B18] and 2 moderate-quality reviews[@B20], [@B25] among teenagers using paroxetine reported significantly elevated risk of suicidal ideation or behavior compared to placebo. And one moderate-quality review in adults using fluvoxamine[@B11] also found elevated risk of suicidal ideation or behavior. None of the other SSRIs considered in the reviews were associated with suicidal ideation or behavior.

### 3.3.3. Results stratified by diagnoses {#s8cc}

As shown in Table 1, three of the included systematic reviews did not specify the diagnosis of the participants;[@B11],[@B23],[@B26] three reviews were restricted to individuals with depressive disorders,[@B7],[@B21],[@B24] and the remaining six reviews considered individuals with a variety of diagnoses.[@B8],[@B18],[@B19],[@B20],[@B22],[@B25] Eight reviews included individuals with depression, five included individuals with obsessive compulsive disorder, four included individuals with anxiety disorders or social anxiety disorder, one included individuals with post-traumatic stress disorder, and one considered individuals with bulimia. As shown in Table 3, only one diagnosis was associated in elevated risk of suicidal ideation or behavior when treated with SSRIs: two of the three moderate-quality systematic reviews of depressed teenagers found that use of SSRIs was significantly associated with increased suicidal ideation or behavior. This effect was not seen in the single high-quality review of depressed teenagers (though there was a trend that suggested an association), in reviews of depressed adults, or in the reviews of any of the other diagnoses considered.

4. Discussion {#s9}
=============

4.1. Main findings {#s9a}
------------------

Over the last decade concern about the possible link between SSRI use and an increased risk of suicide stimulated several large-scale studies that have had a major influence on policies and clinical practice related to the treatment of depression. It is, therefore, concerning to find that only 1 of 12 systematic reviews on this topic - the most scientifically credible information available for making decisions about clinical care - are rated as 'high-quality'. One is left with uncomfortable questions about the quality of other systematic reviews on topics that have received much less funding and attention but are, nevertheless,being used as justification for changing policies and clinical practice. Our study identified several areas where systematic reviews are lacking,including inadequate description of the search strategy, failure to consider the scientific quality of the included studies, and no discussion of the possibility of publication bias[@B28], [@B29], [@B30], [@B31] - issues that can seriously compromise the validity of a review. Clearly, the authors of systematic reviews and the journals that publish systematic reviews need be much more rigorous in their evaluation of the methodological quality of the reviews.

How should the methodological quality of systematic reviews be evaluated? This is a relatively new area of concern that has only become a focus of methodological attention over the last decade, so the techniques for doing this are still evolving. The current study employed the Assessment of Multiple Systematic Reviews (AMSTAR) scale,[@B14],[@B32] the most promising instrument yet available. In our study we found that independent coders of published reports of systematic reviews could reliably assess the overall quality of the report using the 11-item scale (ICC=0.86). But the interrater reliability of several of the individual items in the scale was weak and it was unacceptable for two items which assess (a) the appropriateness of the method of combining findings across studies and (b) the use of publication status as an inclusion criteria. The difficulty of achieving agreement on these items indicates the need to tighten the operational definitions used to code the items, or the need to change the wording of the items to make them less ambiguous. Further work on the validity and utility of the assessment tool is also needed to determine the appropriateness of the current cutoff scores for 'high','moderate', and 'low' methodological quality and to develop strategies for using the information obtained from this assessment of the quality of systematic reviews to inform policy and clinical decisions.

What can be concluded from this evaluation of the quality of systematic reviews on the relationship of SSRI use and suicidal ideation and behavior? Given that only one of the 12 systematic reviews considered was classified as 'high-quality' it is necessary to be somewhat cautious when interpreting the results. Nevertheless, it is reassuring that the high-quality review and 3 of the 8 moderate-quality reviews (but none of the 3 lowquality reviews) came to the same conclusion: SSRI use is associated with an elevated risk of suicidal ideation or behavior. Interpretation of the stratified analyses is difficult because of differences in the number of studies and in the number of participants in the studies in different age groups, using different types of SSRIs, and with different diagnoses. Nevertheless, the general picture is clear: the elevated risk of suicidal ideation and behavior associated with SSRIs is most evident in children and adolescents, particularly those with depressive disorders and those being treated with paroxetine. This conclusion supports the findings of the United States FDA report that highlighted the moderating influence of age and a diagnosis of depression on the relationship between SSRI use and the risk of suicidal ideation and behaviors.[@B9] Our findings are also consistent with those of the British drug regulatory agency which highlighted the risk of self-harm and suicidal behavior among children treated with paroxetine.[@B34]

4.2. Limitations {#s9b}
----------------

There are several potential limitations that need to be considered.

\(a\) The search strategy did not identify a single review about this important topic from China. All identified reports were in English from highincome countries so it is uncertain whether or not the results would hold true in low- and middle-income countries where the use of SSRIs,the help-seeking for depression and other mental disorders,and the demographic pattern of suicidal behavior may be quite different.

\(b\) The measure of quality employed in the study, the AMSTAR scale, is the best currently available measure, but the poor inter-rater reliability of some of the items indicates that further work is needed to improve the reliability and validity of the measure. Reviewers using these criteria need to decide a priori whether or not ancillary web-based materials of included articles will be considered when making the quality determination.

\(c\) The sample sizes available for several of the stratified analyses shown in Table 3 were relatively small, so there were several cases in which an odds ratio of over 2 was not statistically significant. These may be Type II errors. Larger samples in these specific cohorts would be needed to resolve the issue.

###### 

Overall and stratified results of 12 included systematic reviews

  --------------------------------------------------------------------------------------------------------------------------------------------
  study ID                                            age group       SSRI           placebo        odds ratio\                  quality of\
                                                                                                    (95%CI)                       review^a^
  --------------------------------------------------- --------------- -------------- -------------- ---------------------------- -------------
  **OVERALL RESULTS**                                                                                                            

  Beasley 1991[@B7]                                   not specified   30 / 1765      16 / 569       0.60 \[0.32,1.10\]           M

  Khan 2000[@B26]                                     not specified   56 / 5016      13 / 1340      1.15 \[0.63,2.11\]           L

  Fergusson 2005[@B8]                                 not specified   27 / 10,557    9 / 7856       **2.24 \[1.05,4.76\]^b^**    M

  Gunnell 2005[@B11]                                  adults          175 / 23,804   107 / 17,022   1.17 \[0.92,1.49\]           M

  Dubicka 2006[@B24]                                  teenagers       56 / 1135      36 / 987       1.37 \[0.89,2.10\]           M

  Hammad 2006[@B25]                                   teenagers       51 / 1554      25 / 1416      **1.89 \[1.16,3.06\]^b^**    M

  Apter 2006[@B20]                                    teenagers       22 / 642       5 / 549        **3.86 \[1.45,10.26\]^b^**   M

  Bridge 2007[@B18]                                   teenagers       52 / 1839      27 / 1704      **1.81 \[1.13,2.89\]^b^**    H

  Tauscher-Wisniewski 2007[@B19]                      adults          41 / 7066      26 / 4382      0.98 \[0.60,1.60\]           L

  Beasley 2007[@B21]                                  adults          233 / 2200     197 / 1551     0.81 \[0.67,1.00\]           L

  Stone 2009[@B23]                                    not specified   205 / 31,440   141 / 21,225   0.98 \[0.79,1.22\]           M

  Carpenter 2011[@B22]                                adults          83 / 8958      65 / 5953      0.85 \[0.61,1.17\]           M

  **RESULTS STRATIFIED BY TYPE OF SSRI**                                                                                         

  ***Fluoxetine***                                                                                                               

  Beasley 1991[@B7]                                   not specified   30 / 1765      16 / 569       0.60 \[0.32,1.10\]           M

  Dubicka 2006[@B24]                                  teenagers       18 / 358       12 / 321       1.36 \[0.65,2.88\]           M

  Hammad 2006[@B25]                                   teenagers       18 / 358       11 / 321       1.49 \[0.69,3.21\]           M

  Bridge 2007[@B18]                                   teenagers       18 / 410       11 / 372       1.51 \[0.70,3.23\]           H

  Beasley 2007[@B21]                                  adults          233 / 2200     197 / 1551     0.81 \[0.66,1.00\]           L

  Tauscher-Wisniewski 2007[@B19]                      adults          41 / 7066      26 / 4382      0.98 \[0.60,1.60\]           L

  Stone 2009[@B23]                                    not specified   81 / 7180      67 / 4814      0.81 \[0.58,1.12\]           M

  ***Paroxetine***                                                                                                               

  Khan 2000[@B26]                                     not specified   45 / 2963      8 / 554        1.05 \[0.49,2.25\]           L

  Gunnell 2005[@B11]                                  adults          66 / 8481      55 / 5808      0.82 \[0.57,1.18\]           M

  Dubicka 2006[@B24]                                  teenagers       14 / 378       7 / 285        1.53 \[0.61,3.84\]           M

  Hammad 2006[@B25]                                   teenagers       16 / 641       4 / 548        **3.48 \[1.16,10.48\]^b^**   M

  Apter 2006[@B20]                                    teenagers       22 / 642       5 / 549        **3.86 \[1.45,10.26\]^b^**   M

  Bridge 2007[@B18]                                   teenagers       16 / 641       4 / 548        **3.48 \[1.16,10.48\]^b^**   H

  Stone 2009[@B23]                                    not specified   50 / 9919      29 / 6972      1.21 \[0.77,1.92\]           M

  Carpenter 2011[@B22]                                adults          83 / 8958      65 / 5953      0.85 \[0.61,1.17\]           M

  ***Sertraline***                                                                                                               

  Khan 2000[@B26]                                     not specified   11 / 2053      5 / 786        0.84 \[0.29,2.43\]           L

  Gunnell 2005[@B11]                                  adults          30 / 7169      21 / 5108      1.02 \[0.58,1.78\]           M

  Dubicka 2006[@B24]                                  teenagers       5 / 189        2 / 184        2.47 \[0.47,12.91\]          M

  Hammad 2006[@B25]                                   teenagers       5 / 281        3 / 279        1.67 \[0.39,7.04\]           M

  Bridge 2007[@B18]                                   teenagers       5 / 320        3 / 318        1.67 \[0.39,7.03\]           H

  Stone 2009[@B23]                                    not specified   18 / 6363      18 / 6363      0.51 \[0.28,0.93\]           M

  ***Fluvoxamine***                                                                                                              

  Gunnell 2005[@B11]                                  adults          49 / 4186      24 / 3396      **1.66 \[1.02,2.72\]^b^**    M

  Hammad 2006[@B25]                                   teenagers       2 / 57         0 / 63         5.72 \[0.27,121.72\]         M

  Bridge 2007[@B18]                                   teenagers       2 / 120        0 / 128        5.42 \[0.26,114.10\]         H

  Stone 2009[@B23]                                    not specified   22 / 2187      13 / 1828      1.42 \[0.71,2.82\]           M

  ***Citalopram***                                                                                                               

  Gunnell 2005[@B11]                                  adults          22 / 1320      10 / 622       1.04 \[0.49,2.20\]           M

  Dubicka 2006[@B24]                                  teenagers       19 / 210       15 / 197       1.21 \[0.60,2.45\]           M

  Hammad 2006[@B25]                                   teenagers       10 / 217       7 / 205        1.37 \[0.51,3.66\]           M

  Stone 2009[@B23]                                    not specified   24 / 2661      7 / 1371       1.77 \[0.76,4.13\]           M

  ***Escitalopram***                                                                                                             

  Gunnell 2005[@B11]                                  adults          8 / 2648       4 / 2088       1.58 \[0.47,5.25\]           M

  Stone 2009[@B23]                                    not specified   10 / 3130      5 / 2604       1.67 \[0.57,4.88\]           M

  ***Escitalopram or Citalopram^c^***                                                                                            

  Bridge 2007[@B18]                                   teenagers       11 / 348       9 / 338        1.19 \[0.49,2.92\]           H

  **RESULTS STRATIFIED BY TYPE OF MENTAL DISORDER**                                                                              

  ***Depressive disorders***                                                                                                     

  Beasley 1991[@B7]                                   not specified   30 / 1765      16 / 569       0.60 \[0.32,1.10\]           M

  Fergusson 2005[@B8]                                 not specified   17 / 5306      8 / 4370       1.75 \[0.76,4.06\]           M

  Dubicka 2006[@B24]                                  teenagers       56 / 1135      36 / 987       1.37 \[0.89,2.10\]           M

  Hammad 2006[@B25]                                   teenagers       44 / 1070      24 / 963       **1.68 \[1.01,2.78\]^b^**    M

  Apter 2006[@B20]                                    teenagers       18 / 378       5 / 285        **2.80 \[1.03,7.63\]^b^**    M

  Bridge 2007[@B18]                                   teenagers       45 / 1201      26 / 1096      1.60 \[0.98,2.61\]           H

  Beasley 2007[@B21]                                  adults          233 / 2200     197 / 1551     0.81 \[0.67,1.00\]           L

  Carpenter 2011[@B22]                                adults          66 / 3720      47 / 2260      0.85 \[0.58,1.24\]           M

  ***Obsessive-compulsive disorder***                                                                                            

  Hammad 2006[@B25]                                   teenagers       4 / 319        1 / 297        3.76 \[0.42,33.82\]          M

  Apter 2006[@B20]                                    teenagers       1 / 99         0 / 107        3.27 \[0.13,81.31\]          M

  Bridge 2007[@B18]                                   teenagers       4 / 362        1 / 339        3.78 \[0.42,33.96\]          H

  Tauscher-Wisniewski 2007[@B19]                      adults          5 / 421        3 / 144        0.56 \[0.13,2.39\]           L

  Carpenter 2011[@B22]                                adults          5 / 698        4 / 416        0.74 \[0.20,2.78\]           M

  ***Anxiety disorder***                                                                                                         

  Hammad 2006[@B25]                                   teenagers       3 / 165        0 / 156        6.74 \[0.35,131.58\]         M

  Apter 2006[@B20]                                    teenagers       3 / 165        0 / 157        6.78 \[0.35,132.41\]         M

  Bridge 2007[@B18]                                   teenagers       3 / 276        0 / 269        6.90 \[0.35,134.17\]         H

  Carpenter 2011[@B22]                                adults          8 / 2939       8 / 2243       0.76 \[0.29,2.03\]           M

  ***Post-traumatic stress disorder***                                                                                           

  Carpenter 2011[@B22]                                adults          3 / 698        6 / 510        0.36 \[0.09,1.46\]           M

  ***Bulimia***                                                                                                                  

  Tauscher-Wisniewski 2007[@B19]                      adults          18 / 722       8 / 410        1.28 \[0.55,2.98\]           L
  --------------------------------------------------------------------------------------------------------------------------------------------

SSRI,selective serotonin reuptake inhibitor; CI,confidence interval

^a^ methodological quality categorized as high (H),moderate (M), or low (L)

^b^ statistically significant difference in number of suicidal events between SSRI and placebo

^c^ in this study results for escitalopram and citalopram were analyzed together, not separately

\(d\) Different studies considered in the reviews used different methods of assessing the outcome measure. Most studies used the United States FDA definition of suicide-related events[@B35] to measure suicide, suicidal ideation,and suicidal behaviors, while a minority of studies[@B20], [@B21] use the single suicide-related item from the Hamilton Depression Scale (HAMD)[@B36] which asks about suicidal ideation.

\(e\) Suicidal ideation has a weak association with suicidal behavior - particularly in youth---while prior suicide attempt is, by far, the strongest predictor of subsequent death by suicide. Thus, these are two distinct types of events, but most studies considered in the included reviews combine these two phenomena as the target outcome, primarily because the low rate of suicide attempt makes it difficult to achieve statistical power. Collapsing these two types of events in the analysis weakens the clinical utility of the results.

\(f\) It was not possible to stratify results by several other potentially important variables including the time in the course of treatment (suicide risk may be greatest during the early stages of treatment[@B11]),and the dose of the SSRI.

4.3. Implications {#s9c}
-----------------

We found a surprisingly wide range in the methodological quality of systematic reviews about the relationship of SSRI use and risk of suicidal ideation and behavior. This highlights the importance of routinely assessing the quality of systematic reviews - assumed to provide 'gold standard' information - and of working to improve the quality of systematic reviews about this issue and about other issues of policy or clinical importance. After consideration of the quality of the available systematic reviews,our overall findings are in line with the recommendations of the United States and British drug regulatory agencies: the use of SSRIs is associated with an increase in suicidal ideation or behavior,but this increased risk is primarily limited to children and adolescents,particularly those who have depression and those who are treated with paroxetine.
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